Few Duchenne muscular dystrophy (DMD) treatments have generated as much excitement, controversy, and debate as Elevidys (delandistrogene moxeparvovec), the gene therapy developed by Sarepta Therapeutics.
For many families, Elevidys represents hope. It is the first approved gene therapy designed to address the underlying genetic cause of Duchenne muscular dystrophy by delivering a micro-dystrophin gene to muscle cells. The treatment received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2023 and later expanded approval in 2024.
Yet at the same time, Sarepta’s stock has experienced dramatic declines, regulatory controversies have emerged, safety concerns have intensified, and many scientists continue to debate the true magnitude of clinical benefit.
This situation raises difficult but important questions:
- If Elevidys works, why has Sarepta’s stock collapsed?
- Do investors believe the treatment is ineffective?
- Why did clinical trials fail to meet some major endpoints?
- Why is Elevidys approved by the FDA but not approved by the European Medicines Agency (EMA)?
- What should families understand before deciding whether to pursue treatment?
- Could accepting Elevidys today affect eligibility for future therapies?
These questions deserve evidence-based answers rather than emotional social media debates.
Table of Contents
Understanding What Elevidys Actually Does
Elevidys Is Not a Full Dystrophin Replacement
Duchenne muscular dystrophy occurs because mutations in the DMD gene prevent production of functional dystrophin, a critical protein that protects muscle fibers from damage.
Elevidys does not restore the complete dystrophin gene.
Instead, it delivers a shortened version called micro-dystrophin using an adeno-associated virus (AAV) vector. The therapy was designed because the full dystrophin gene is too large to fit inside current AAV delivery systems.
This distinction is important.
The therapy aims to produce a smaller dystrophin-like protein that may partially protect muscle cells, but it does not recreate the complete natural dystrophin protein found in healthy individuals. Studies have demonstrated sustained micro-dystrophin expression after treatment, which served as a key basis for FDA approval.
If Elevidys Works, Why Has Sarepta’s Stock Fallen So Dramatically?
Many families assume that a falling stock price automatically means a treatment does not work.
In biotechnology, the reality is far more complicated.
Investor Concerns Extend Beyond Clinical Results
Investors evaluate:
- Safety risks
- Regulatory uncertainty
- Commercial adoption
- Insurance reimbursement
- Future competition
- Long-term efficacy
rather than simply asking whether a treatment produces some benefit.
Safety Concerns Have Had Major Impact
During 2025, acute liver failure cases and patient deaths associated with gene therapy programs intensified scrutiny from regulators and investors.
The FDA later updated Elevidys prescribing information and added stronger safety warnings regarding acute serious liver injury and acute liver failure.
Although these events occurred primarily among non-ambulatory patients, they significantly affected investor confidence.
Investors worry not only about whether a therapy works, but whether regulators may restrict its use in the future.
Clinical Trial Results Have Been Interpreted Differently
One major source of controversy is the EMBARK Phase 3 study.
The original placebo-controlled EMBARK trial failed to achieve its primary endpoint involving improvement in North Star Ambulatory Assessment (NSAA) scores compared with placebo.
However, multiple secondary endpoints favored Elevidys, and later analyses suggested slowing of disease progression.
Supporters argue that Duchenne progression is slow and difficult to measure over short time periods.
Critics argue that missing a primary endpoint should raise questions regarding efficacy.
The result is scientific disagreement rather than scientific consensus.
Why Viral Videos Should Not Be Used as Scientific Evidence
Families often encounter dramatic social media videos showing children before and after treatment.
These videos can be emotionally powerful.
However, they are not scientific evidence.
The Problem With Anecdotal Evidence
A child may appear:
- stronger
- faster
- more energetic
- more stable
for many reasons unrelated to treatment.
Factors include:
- growth
- physiotherapy
- corticosteroid use
- motivation
- natural variability
A short video clip cannot determine whether a treatment modifies disease progression.
Objective Biomarkers Matter More
Families should request transparent reporting of:
CK (Creatine Kinase)
CK is one of the most important biomarkers in Duchenne.
When muscle cells are damaged, CK leaks into the bloodstream.
Lower CK levels after treatment may indicate reduced muscle injury.
AST and ALT
AST and ALT are often viewed as liver enzymes.
However, in Duchenne, elevated AST and ALT may also originate from damaged muscle tissue.
Tracking these markers over time can provide important insights into both muscle health and treatment safety.
If Elevidys truly protects muscle fibers, many experts argue that CK trends deserve as much attention as functional outcomes.
Read More: Why CK, AST, and ALT Data Matter More Than Videos in Duchenne Gene Therapy
Are NSAA Scores Enough to Measure Success?
What Is NSAA?
The North Star Ambulatory Assessment is widely used in Duchenne clinical trials.
It evaluates activities such as:
- standing
- walking
- climbing
- jumping
Higher scores indicate better motor function. Learn More: What is NSAA?
The Limitations of NSAA
NSAA can be influenced by:
- age
- motivation
- fatigue
- evaluator differences
- learning effects
A child may improve temporarily without experiencing meaningful biological improvement.
For this reason, many researchers believe NSAA should be interpreted alongside biological markers.
Why Dystrophin Production Matters
Ultimately, Duchenne is caused by lack of dystrophin.
A therapy designed to replace dystrophin should ideally demonstrate:
- robust protein production
- sustained expression
- muscle preservation
- long-term functional benefit
Micro-dystrophin production was a major reason FDA reviewers considered Elevidys biologically active.
However, scientists continue debating how much micro-dystrophin is necessary to produce meaningful clinical benefit.
Read More: NSAA Alone Is Not Enough
How many more years will my son live after receiving Elevidys?
This is perhaps the most important question families ask.
Unfortunately, nobody knows.
No Survival Benefit Has Yet Been Proven
Elevidys has not existed long enough to demonstrate whether it extends life expectancy by:
- 2 years
- 5 years
- 10 years
- 20 years
Long-term survival studies simply do not exist yet.
Any claim regarding exact lifespan extension is currently speculation.
What Clinical Trials Suggest
Recent follow-up analyses suggest that Elevidys may slow disease progression compared with natural history cohorts.
If slowing progression is confirmed over longer periods, this could theoretically delay:
- loss of ambulation
- respiratory decline
- cardiac complications
However, proving survival extension requires many additional years of observation.
Families should understand that current evidence demonstrates biological activity and potential functional benefit—not proven life extension.
Read More: How Much Does Elevidys Gene Therapy Improve the Condition of Children With DMD?
Is Elevidys Worth 3.2 Million U.S. Dollars?
The reported cost of Elevidys is approximately 3.2 million U.S. dollars per treatment.
This makes it one of the most expensive medicines in history.
The Economic Question
Value depends on:
- magnitude of benefit
- duration of benefit
- safety profile
- future treatment options
If a therapy adds decades of healthy life, many would argue it is worthwhile.
If benefit proves modest, the value proposition becomes more controversial.
At present, the true long-term value remains uncertain because long-term outcomes remain unknown.
Why Is Elevidys Approved by the FDA but Not by the EMA?
Many families assume that approval by one regulator guarantees approval elsewhere.
This is not always true.
Different Regulatory Standards
The FDA and EMA may evaluate:
- risk tolerance
- clinical endpoints
- statistical evidence
- unmet medical need
differently.
The FDA has historically shown willingness to use accelerated approval pathways for severe diseases lacking treatment options.
European regulators sometimes require stronger confirmatory evidence before approval.
This does not necessarily mean one agency is right and the other is wrong.
It reflects different interpretations of the available evidence.
Learn More: Why Elevidys Was Not Approved by the European Medicines Agency (EMA)?
Could Receiving Elevidys Limit Future Treatment Options?
This question deserves far more discussion than it often receives.
The AAV Antibody Problem
Elevidys uses an AAV vector.
After treatment, the immune system may develop antibodies against that vector.
This creates challenges for future re-dosing.
Potential Impact on Future Gene Therapies
Many next-generation gene therapies also rely on AAV technologies.
Families should ask:
- Will future treatments use similar vectors?
- Will I still qualify?
- Are re-dosing strategies being developed?
- What alternatives may become available?
These discussions should occur before treatment, not after.
What New Duchenne Therapies Are Coming?
The Duchenne pipeline is evolving rapidly.
Next-Generation Gene Therapies
Several companies are developing improved approaches intended to increase dystrophin expression or improve safety. Read More: Potential Upcoming New Gene Therapies for Duchenne
Cell Therapies
Researchers are exploring cell-based therapies that may regenerate damaged muscle tissue.
mRNA Therapies
Emerging mRNA approaches aim to enable production of full-length dystrophin rather than micro-dystrophin.
This strategy has attracted considerable attention because it may overcome size limitations associated with AAV vectors.
Gene Editing
CRISPR-based approaches remain experimental but offer the possibility of permanent genetic correction.
Full-Length Dystrophin Strategies
Many researchers consider full-length dystrophin restoration the ultimate goal because it most closely resembles natural biology.
Whether future therapies achieve this safely remains unknown.
Why Families Continue Campaigning for Elevidys
Critics sometimes assume families are uninformed.
This assumption is often unfair.
Most families understand that Duchenne is relentlessly progressive.
Every year matters.
Every month matters.
Parents frequently choose treatment because they fear losing an opportunity that may never return.
Supporters argue:
- waiting carries risks
- disease progression continues
- future therapies are uncertain
Skeptics argue:
- evidence remains incomplete
- long-term benefit is unknown
- future therapies may offer greater advantages
Both perspectives are understandable.
Questions Every Family Should Ask Before Choosing Elevidys
- What evidence demonstrates biological benefit?
- What evidence demonstrates functional benefit?
- What long-term safety data exist?
- What happens if better therapies become available?
- Could future eligibility be affected?
- What are my child’s current disease characteristics?
- How does the risk-benefit profile apply specifically to my child?
No social media video can answer these questions.
Only careful review of evidence and consultation with experienced neuromuscular specialists can.
Learn More: Frequently Asked Questions About Elevidys
Conclusion
The debate surrounding Elevidys illustrates one of the most difficult challenges in modern medicine: making life-changing decisions in the presence of uncertainty.
There is little doubt that Elevidys produces micro-dystrophin and demonstrates biological activity. Long-term follow-up data also suggest that disease progression may be slowed in at least some patients. However, important questions remain regarding durability, safety, survival benefit, cost-effectiveness, and the treatment’s impact on future therapeutic options.
Supporters of Elevidys often point to FDA approval and promising clinical findings. Critics, meanwhile, argue that greater transparency is needed regarding biomarkers such as CK, AST, ALT, long-term functional outcomes, and survival expectations. These unresolved questions continue to fuel debate within the Duchenne community.
The dramatic decline in Sarepta’s share price—from approximately 122 U.S. dollars to 15 U.S. dollars in roughly 15 months—is not a typical fluctuation for a biotechnology company. While stock performance alone cannot determine whether a treatment works or does not work, such a substantial loss of market value suggests that many investors have become increasingly concerned about the available data, safety developments, regulatory uncertainty, future competition, and the overall risk-benefit profile of the therapy. Whether those concerns ultimately prove justified remains to be seen, but the decline clearly reflects a significant loss of investor confidence.
For families, however, the most important question is not whether investors trust Elevidys. The most important question is whether the currently available evidence is sufficient to justify treatment today, or whether waiting for additional data and next-generation therapies may be the better choice for their child. Every family deserves transparent information, honest discussions about uncertainties, and access to all available evidence before making a decision that could shape their child’s future.
One final thought: if someone tells you, “CK doesn’t matter,” don’t accept that claim without evidence. Duchenne muscular dystrophy is a disease defined by ongoing muscle damage, and CK is one of the clearest indicators of that damage. If CK levels are important when diagnosing and monitoring Duchenne, they remain important after Elevidys. Transparency regarding CK trends should be considered a necessity, not an option.
As DMDWarrior, we submitted a series of questions to Sarepta regarding topics that many Duchenne muscular dystrophy families frequently ask about, including clinical outcomes, biomarkers, long-term expectations, and future treatment considerations. We were informed that responses would be provided, but as of the publication of this article, we have not received detailed answers to those questions. Should Sarepta choose to respond at any time, we are prepared to publish their answers in full so that patients, families, and healthcare professionals can review the information directly and draw their own conclusions.
Follow This Page >>> All Clinical Trials for Duchenne
